一般演題（口演）45 ALK・ROS1融合遺伝子陽性肺癌

[O45-6] Repotrectinib in TKI-naïve patients with advanced ROS1+NSCLC：Phase 1/2 TRIDENT-1 trial update

^○Koichi Goto¹, Alexander Drilon², Rafal Dziadziuszko³, D. Ross Camidge⁴, Jessica J. Lin⁵, Benjamin Besse⁶, Sang-We Kim⁷, Ki Hyeong Lee⁸, Benjamin J. Solomon⁹, Misako Nagasaka¹⁰, Jurgen Wolf¹¹, Adrianus Johannes de Langen¹², Parneet Cheema¹³, Nong Yang¹⁴, Vamsidhar Velcheti¹⁵, Yasir Elamin¹⁶, Yuanfang Xu¹⁷, Christophe Y. Calvet¹⁷, Felipe Ades¹⁷, Byoung Chul Cho¹⁸ (1.National Cancer Center Hospital East, Kashiwa, Japan, 2.Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA, 3.Medical University of Gdansk, Early Clinical Trials Centre, Gdansk, Poland, 4.University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA, 5.Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 6.Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France, 7.Asan Medical Center, Seoul, South Korea, 8.Chungbuk National University Hospital, Cheongju-si, South Korea, 9.Peter MacCallum Cancer Centre, Melbourne, Australia, 10.University of California Irvine, School of Medicine, Orange, CA, USA, 11.Centrum für Integrierte Onkologie – Uniklinik Köln, Köln, Germany, 12.Netherlands Cancer Institute, Amsterdam, The Netherlands, 13.William Osler Health System, University of Toronto, Brampton/Toronto, Ontario, Canada, 14.Hunan Cancer Hospital, Hunan, China, 15.NYU Perlmutter Cancer Center, New York, NY, USA, 16.University of Texas MD Anderson Cancer Center, Houston, TX, USA, 17.Bristol Myers Squibb, Princeton, NJ, USA, 18.Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea)

アンコール演題